---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020097"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:36:34.364735+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma reports Q1 net loss $19.1M; PC14586 trial advances

## Summary
- Net loss Q1 2023 $19.1M vs $18.4M Q1 2022; cash & equivalents $229.4M.
- R&D expenses $15.1M (up from $11.8M) due to increased clinical costs for PC14586.
- Phase 1/2 PYNNACLE study of PC14586 ongoing; next update expected in 2H 2023.
- Enrollment commenced in combination arm of PC14586 with KEYTRUDA (pembrolizumab).
- Net cash used in operations $15.0M vs $18.0M in prior year period.

## SEC filing metadata
- accession: 0000950170-23-020097
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017023020097/0000950170-23-020097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017023020097/pmvp-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020097
- JSON: https://secwatch.observer/filing/0000950170-23-020097.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020097.txt

## Key facts
- Earnings Releases
  PMV Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023, was $19.1 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: Net loss for the quarter ended March 31, 2023, was $19.1 million
  - Result: reported results
  source text: PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000095017023020097/0000950170-23-020097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.